PT689449E - Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina - Google Patents

Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina

Info

Publication number: PT689449E
Authority: PT; Portugal
Prior art keywords: pct; muramilo; citoquin; peptide; association
Prior art date: 1993-03-19

Application number

PT94910445T

Other languages

English (en)

Inventor

Georges Bahr

Pierre Lefrancier

Louis Chedid

Original Assignee

Vacsyn Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-19

Filing date

1994-03-21

Publication date

2003-03-31

1993-03-19 Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr

1993-03-31 Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr

1994-03-21 Application filed by Vacsyn Sa filed Critical Vacsyn Sa

2003-03-31 Publication of PT689449E publication Critical patent/PT689449E/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT94910445T 1993-03-19 1994-03-21 Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina PT689449E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9303230A FR2702659B1 (fr)	1993-03-19	1993-03-19	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr)	1993-03-31	1993-03-31	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .

Publications (1)

Publication Number	Publication Date
PT689449E true PT689449E (pt)	2003-03-31

Family

ID=26230187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT94910445T PT689449E (pt)	1993-03-19	1994-03-21	Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina

Country Status (11)

Country	Link
US (1)	US5932208A (pt)
EP (1)	EP0689449B1 (pt)
JP (1)	JP3723206B2 (pt)
AT (1)	ATE226828T1 (pt)
AU (1)	AU6285694A (pt)
CA (1)	CA2157758A1 (pt)
DE (1)	DE69431620T2 (pt)
DK (1)	DK0689449T3 (pt)
ES (1)	ES2187520T3 (pt)
PT (1)	PT689449E (pt)
WO (1)	WO1994021275A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US6267968B1 (en) *	1995-04-07	2001-07-31	Vacsyn S.A.	MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
DE69738948D1 (de)	1996-12-06	2008-10-09	Amgen Inc	Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US6013253A (en) *	1997-08-15	2000-01-11	Amgen, Inc.	Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CZ304942B6 (cs)	2000-03-31	2015-02-04	Purdue Research Foundation	Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
FR2809106A1 (fr) *	2000-05-17	2001-11-23	Istac	Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
EP1414517A4 (en) *	2001-06-26	2008-02-06	Photomed Technologies Inc	MULTIPLE WAVELENGTH ILLUMINATOR
CN1547486A (zh)	2001-06-26	2004-11-17		抗opgl抗体
DK1434603T3 (da) *	2001-09-28	2010-04-26	Purdue Research Foundation	Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater
US20030097409A1 (en) *	2001-10-05	2003-05-22	Hungchou Tsai	Systems and methods for securing computers
EA018072B1 (ru)	2002-09-06	2013-05-30	Амджен Инк.	Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
JP2006517191A (ja) *	2002-12-30	2006-07-20	アムジエン・インコーポレーテツド	共刺激因子を用いた併用療法
US7546638B2 (en) *	2003-03-18	2009-06-09	Symantec Corporation	Automated identification and clean-up of malicious computer code
PL3138566T3 (pl) *	2003-11-17	2022-03-07	Biomarin Pharmaceutical Inc.	Leczenie fenyloketonurii z użyciem bh4
WO2006055511A2 (en) *	2004-11-17	2006-05-26	Biomarin Pharmaceutical Inc.	Stable tablet formulation of tetrahydrobiopterin
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
US8168164B2 (en) *	2006-02-03	2012-05-01	Purdue Research Foundation	Targeted conjugates and radiation
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2009062339A1 (en)	2007-11-14	2009-05-22	General Regeneratives, Ltd.	Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en)	2011-07-22	2014-08-21	Amgen Inc.	Il-17 receptor a is required for il-17c biology
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
WO2015191783A2 (en)	2014-06-10	2015-12-17	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
WO2018022982A1 (en)	2016-07-29	2018-02-01	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US20210236599A1 (en)	2018-08-13	2021-08-05	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en)	2022-05-16	2023-11-23	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK585886A (da) *	1985-12-24	1987-06-25	Takeda Chemical Industries Ltd	Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) *	1986-08-13	1987-12-31	Takeda Chemical Industries Ltd	Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) *	1988-02-13	1988-03-16	Ciba Geigy Ag	Antiviral combination

1994
- 1994-03-21 PT PT94910445T patent/PT689449E/pt unknown
- 1994-03-21 WO PCT/FR1994/000307 patent/WO1994021275A1/fr active IP Right Grant
- 1994-03-21 AT AT94910445T patent/ATE226828T1/de not_active IP Right Cessation
- 1994-03-21 EP EP94910445A patent/EP0689449B1/fr not_active Expired - Lifetime
- 1994-03-21 US US08/522,342 patent/US5932208A/en not_active Expired - Fee Related
- 1994-03-21 JP JP52072694A patent/JP3723206B2/ja not_active Expired - Fee Related
- 1994-03-21 AU AU62856/94A patent/AU6285694A/en not_active Abandoned
- 1994-03-21 CA CA002157758A patent/CA2157758A1/en not_active Abandoned
- 1994-03-21 DK DK94910445T patent/DK0689449T3/da active
- 1994-03-21 ES ES94910445T patent/ES2187520T3/es not_active Expired - Lifetime
- 1994-03-21 DE DE69431620T patent/DE69431620T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP3723206B2 (ja)	2005-12-07
EP0689449A1 (fr)	1996-01-03
US5932208A (en)	1999-08-03
DK0689449T3 (da)	2003-03-03
DE69431620T2 (de)	2003-07-03
DE69431620D1 (de)	2002-12-05
EP0689449B1 (fr)	2002-10-30
JPH08511235A (ja)	1996-11-26
WO1994021275A1 (fr)	1994-09-29
AU6285694A (en)	1994-10-11
CA2157758A1 (en)	1994-09-29
ATE226828T1 (de)	2002-11-15
ES2187520T3 (es)	2003-06-16

Publication	Publication Date	Title
PT689449E (pt)	2003-03-31	Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina
Sachs et al.	2002	Tumour necrosis factor-α, interleukin-1β and interleukin-8 induce persistent mechanical nociceptor hypersensitivity
Lacey et al.	1993	IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1, 25 dihydroxyvitamin D3.
WO2002068470A3 (en)	2002-12-05	Interferon-alpha induced gene
GR3032037T3 (en)	2000-03-31	Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
HK1030157A1 (en)	2001-04-27	Use of consensus interferon and compositions comprising consensus interferon.
NO965621D0 (no)	1996-12-30	Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
MX9703889A (es)	1997-08-30	Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion.
IE58963B1 (en)	1993-12-01	Y-ifn as active substance for inhibiting (preventing) degradation process in bone
DK0613499T3 (da)	1998-09-23	Humame IT-4-mutantproteiner
Morhenn	1986	The etiology of lichen planus: a hypothesis
YU199691A (sh)	1994-06-24	Receptor za humani interleukin-5
CA2388338A1 (en)	2001-05-03	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
ES2051714T3 (es)	1994-07-01	Un procedimiento para la preparacion de un fragmento de interferon inmune recombinante homogeneo.
Suzuki et al.	2001	Serum levels of interleukin 15 in patients with rheumatic diseases.
DE69127974T2 (de)	1998-02-12	Peptide und deren verwendung
DE60233654D1 (de)	2009-10-22	Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
DK0862454T3 (da)	2002-12-30	CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
BR9713096A (pt)	2000-10-24	Lactação bovina associada à proteìna imunotrópica (cd14), gene codificado e aplicação na ativação de célula b
Femandez‐Botran et al.	1996	Control of the production of soluble interleukin‐4 receptors: implications in immunoregulation
AU6942896A (en)	1997-03-27	Use of muteins of wild-type cytokines as immunogens
DE69836278D1 (de)	2006-12-07	Allele formen von menschlichem stat3
Lammie et al.	1988	Partial characterization of a fibroblast-stimulating factor produced by cloned murine T lymphocytes.
WO2002048182A3 (en)	2002-09-06	Interferon-alpha induced gene
Yasuji et al.	1989	Spontaneous release of B lymphocyte-enhancing factors for growth and differentiation by YH-1 cells in serum-free culture media-Identification of interleukin 1 activities.